{"entity":{"id":"checkpoint-therapeutics","kind":"company","name":"Checkpoint Therapeutics","aka":["Checkpoint Therapeutics, Inc."],"tldr":"Checkpoint Therapeutics developed cosibelimab, an anti-PD-L1 antibody approved by the FDA in December 2024 for advanced cutaneous squamous cell carcinoma, and became part of Sun Pharma in May 2025.","summary":"Checkpoint Therapeutics, a Massachusetts company founded within Fortress Biotech, developed cosibelimab (Unloxcyt), an anti-PD-L1 antibody with an intact Fc region designed to add antibody-dependent cell killing to checkpoint blockade. The FDA approved it in December 2024 for metastatic or locally advanced cutaneous squamous cell carcinoma not curable by surgery or radiation, after an earlier complete response letter over a manufacturing site. Sun Pharmaceutical Industries completed its acquisition of the company on 30 May 2025, paying USD 4.10 a share in cash plus a contingent value right worth up to USD 0.70 a share, and Checkpoint continues as a wholly owned Sun Pharma subsidiary. Company facts are from the official website, FDA approval records and Checkpoint's closing filing with the SEC.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.checkpointtherapeutics.com/"},{"label":"SEC Form 8-K: completion of the Sun Pharma merger (30 May 2025)","url":"https://www.sec.gov/Archives/edgar/data/1651407/000110465925054628/tm2516558d1_8k.htm"},{"label":"FDA: oncology and hematologic malignancies approval notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["cutaneous-scc"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["cosibelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Freshened 29 October 2026: completion of the Sun Pharma merger confirmed from Checkpoint's Form 8-K of 30 May 2025. On 29 October 2026 checkpointtherapeutics.com did not resolve and checkpointtx.com, which a search listing showed carrying the company's own note of the closing, returned HTTP 503; the old domain is kept in the record until a working company page can be confirmed."],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Waltham, MA","country":"US","companyType":"biotech","website":"https://www.checkpointtherapeutics.com/","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2025,"source":"https://www.sec.gov/Archives/edgar/data/1651407/000110465925054628/tm2516558d1_8k.htm","note":"Merger agreement dated 9 March 2025, completed 30 May 2025: USD 4.10 per share in cash plus one contingent value right of up to USD 0.70 per share; the filing does not state a total deal value"}],"acquiredBy":"sun-pharma"},"route":"/companies/checkpoint-therapeutics/","neighbours":{"cancer":[{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"cosibelimab","kind":"drug","name":"Cosibelimab","route":"/drugs/cosibelimab/"}],"company":[{"id":"sun-pharma","kind":"company","name":"Sun Pharmaceutical Industries","route":"/companies/sun-pharma/"}],"trial":[{"id":"ck-301-101","kind":"trial","name":"CK-301-101","route":"/trials/ck-301-101/"},{"id":"nct04786964","kind":"trial","name":"Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC","route":"/trials/nct04786964/"}],"paper":[{"id":"paper-ck-301-101-jitc-2023","kind":"paper","name":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","route":"/key-papers/paper-ck-301-101-jitc-2023/"}]}}